US Hereditary Angioedema Association and four corporate partners endow center to treat rare hereditary swelling disease —
It is rare for an “orphan” disease (typically a condition that affects fewer than 200,000 people nationwide) to have a specific center dedicated to providing treatment and research. And it is even more unusual for big pharmaceutical companies to invest in an endowment to fund this type of center. Fortunately, the US Hereditary Angioedema Association (HAEA), a nonprofit patient advocacy organization, along with four pharmaceutical companies—Shire Human Genetics Therapies Inc., ViroPharma Incorporated (which merged with Shire), Dyax Corp. and CSL Bering—pledged a total of $4.6 million to help make the US HAEA Angioedema Center at UC San Diego Health System a reality. A number of individuals, including those with the disease, also provided private support. … Read the full story from the UC San Diego News Center
Dr. Bruce Zuraw is director of the US HAEA Angioedema Center at UC San Diego Health System and inaugural recipient of the US HAEA Endowed Chair at UC San Diego. He is professor of medicine and chief of the Division of Rheumatology, Allergy & Immunology.
Marc Riedl, MD, MS, associate professor of medicine, is clinical director of the center.